Teerenpeli From Finland is the Best Whisky Producer in the World 2020
8.12.2020 16:43:00 EET | Business Wire | Press release
Lahti-based Teerenpeli Brewery & Distillery has been awarded as the “Worldwide whisky producer” in one of the world’s largest alcohol competitions, the International Wine and Spirit Competition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201208005705/en/
Lahti-based Teerenpeli Brewery and Distillery has been awarded as the “Worldwide whisky producer” in one of the world’s largest alcohol competitions, the International Wine and Spirit Competition. Photo by Teerenpeli.
Hundreds of distilleries from around the world took part in the international competition in London. Four skillful producers were invited to the final round as a nominee for the Best Worldwide Whisky Producer 2020. The nominees with Teerenpeli this year were Kavalan Distillery from Taiwan, Sazerac Company from the United States, and The Lark Distillery from Australia in the category for Scotch Whisky producers.
“It was a great honor for us to receive the first candidacy in Finland. But the fact that we won the series is, of course, a tremendous recognition of almost 20 years of work”, says Mr. Samuli Korhonen, General Manager of Teerenpeli Brewery & Distillery.
Mr. Anssi Pyysing, Entrepreneur and CEO of Teerenpeli, considers the victory a big surprise but he also sees many good reasons for it. “The location of Teerenpeli Distillery is perfect for whisky-making. The groundwater filtered by the Salpausselkä ridges is the best in the world. Barley is grown in local fields and after harvesting, it is malted in the town of Lahti just next to Teerenpeli Distillery. On top of that adding all the experience, skill, and passion of the excellent staff at Teerenpeli, you end up being the best in the world.”
The IWSC awarded Teerenpeli Distillery whiskies with top mentions in the summer. The Whisky Producer of the Year award completed Teerenpeli's rise as a world-class whisky maker, Korhonen describes.
This year, Teerenpeli signed new export agreements in Belgium, Luxembourg and the Netherlands. Whisky exporting to Germany and Sweden is also increasing, and an agreement with a Swedish importing company is going to take Teerenpeli Kaski whisky to Systembolaget stores as the first Finnish whisky.
Teerenpeli Group is a family business owned by Anssi and Marianne Pyysing. Company runs whisky distillery and brewery in Lahti, Finland and ten restaurants all over Finland. Teerenpeli Group was established in 1994 and employs more than 100 people.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005705/en/
Contact information
Samuli Korhonen, General Manager
Teerenpeli Brewery & Distillery
+358 40 861 1081
samuli.korhonen@teerenpeli.com
Anssi Pyysing, CEO, entrepreneur
Teerenpeli Group
+358 500 830 458
anssi.pyysing@teerenpeli.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 10:00:00 EEST | Press release
Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization. "Drug discovery increasingly requires seamless integration between chemistry and biology," said Michael Dabrowski, Chief Executive Officer of Pelago Bioscience. "By bringing RG Discovery
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom